Our results also demonstrated a consistent, but modest, sensitivity of p190-cell lines to IFNα treatment alone, and it was further enhanced with imatinib combination treatment, which could be an attractive treatment option for further investigation in high-risk p190-CML patients. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.